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Two Epstein–Barr virus (EBV) types are known, EBV1 and EBV2, which possess substantially diverged alleles for latency genes EBNA-2,
EBNA-3A, EBNA-3B and EBNA-3C but are thought to be otherwise similar. We report the first complete EBV2 genome sequence, for strain
AG876, as 172,764 bp. The sequence was interpreted as containing at least 80 protein coding genes. Comparison with the published EBV1
sequence demonstrated that the two sequences are collinear and, outside the known diverged alleles, generally very close. The EBNA-1 gene was
identified as another diverged locus, although its variation is believed not to correlate with EBV type. Patterns of substitution between the two
genomes presented a wide spectrum of classes of change. No evidence was seen for involvement of B-cell-specific hypermutation systems in
generation of the diverged alleles. Overall, genomic comparisons indicated that the two EBV types should be regarded as belonging to the same
virus species.
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Epstein–Barr virus (EBV) (family, Herpesviridae; subfam-
ily, Gammaherpesvirinae; genus, Lymphocryptovirus; species,
Human herpesvirus 4) is present at high frequencies in all
human populations and has been investigated extensively,
primarily on account of its association with several human
malignancies. The complete genomic sequence of EBV strain
B95-8 (derived from a case of infectious mononucleosis; Miller
and Lipman, 1973) was published by Baer et al. (1984) and has
since played a central role in EBV research. It emerged during
the 1980s that there are two distinct types of EBV, referred to
here as EBV1 and EBV2 (the terms EBVA and B are also used)
(reviewed by Kieff and Rickinson, 2001; Zimber et al., 1986).
The sequenced B95-8 strain is of type 1, but no complete type 2
genome sequence has been available. The types are defined by
their versions of four latent cycle genes (encoding EBNA-2,
EBNA-3A, EBNA-3B and EBNA-3C), which show pro-
nounced differences in their sequences between EBV1 and
EBV2 (Dambaugh et al., 1984; Rowe et al., 1989; Sample et al.,
1990). The EBNA-3 genes form a contiguous genomic block,⁎ Corresponding author. Fax: +44 141 337 2236.
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doi:10.1016/j.virol.2006.01.015and the EBNA-2 gene is in a non-adjacent location; all these
genes are thought to act in the establishment or maintenance of
latent states of EBV in growth-transformed B lymphocytes
(reviewed by Kieff and Rickinson, 2001). Apart from these four
genes, the genomic sequences of the two types are judged to be
generally closely similar, as evaluated by restriction mapping
and limited sequencing of type 2 strains. Another latent cycle
gene, EBNA-1, is also known to vary among strains, but this
variation is not thought to correlate with the EBV1 and EBV2
types (Bhatia et al., 1996; Habeshaw et al., 1999; MacKenzie et
al., 1999; Wrightham et al., 1995). EBNA-1 has roles in
initiation of genome replication and transcriptional regulation
during latency (reviewed by Leight and Sugden, 2000). Both
EBV types are widely distributed in human populations and
appear to have near equivalent biological properties, although
lymphocytes transformed to an indefinite growth phenotype
by EBV1 propagate more vigorously than cells transformed by
EBV2 (Rickinson et al., 1987), and EBNA-2 is a major
determinant of this phenotype (Cohen et al., 1989). While
most EBV isolates examined are cleanly of one type or the
other, occurrences of natural recombinants that disrupt the
typical allele associations have been reported (Burrows et al.,
1996; Midgley et al., 2000; Shim et al., 1998; Yao et al.,
1996).
165A. Dolan et al. / Virology 350 (2006) 164–170Both the evolutionary origin of the two EBV types and any
functional significance of the differences in four latent cycle
genes remain obscure. In principle, the observed pattern of
diverged alleles in two genomic regions might have arisen by
recombination events involving at least two ancestral lympho-
cryptoviruses (LCVs) or through processes of mutation within a
single lineage; neither of these possible routes presents as
unproblematic (McGeoch, 2001; McGeoch and Davison,
1999). The existence of the two genomic types is thus a chal-
lenge for our understanding of the evolutionary antecedents of
this ubiquitous human pathogen. In order to analyze further the
phenomenon of EBV types, we have determined the complete
genome sequence for the commonly studied EBV2 isolate
AG876, which originated from a Ghanaian case of Burkitt's
lymphoma (Pizzo et al., 1978). In this paper, we report cha-
racteristics of the AG876 sequence and employ it to compile
and evaluate a genome-wide comparison with the EBV1 B95-
8 sequence. In addition, the availability of the EBV2 genomic
sequence afforded an opportunity to update details of the EBV1
B95-8 sequence and its annotation, and we extended compar-
ative evaluations to the two other LCVs whose genomes have
been sequenced, Cercopithecine herpesvirus 15 (CeHV-15;
rhesus lymphocryptovirus) (Rivailler et al., 2002a) and Calli-
trichine herpesvirus 3 (CalHV-3; marmoset lymphocryptovirus)
(Rivailler et al., 2002b).
Results
Determination of the genome sequence of EBV2 strain AG876
The complete genomic DNA sequence of EBV2 strain
AG876 was determined using eight cosmid-cloned fragments,
supplemented by PCR amplification of selected regions. A
listing of the AG876 sequence was assembled to correspond to
conventions used in the data library entries for the EBV1 B95-
8 sequence (accession numbers V01555 and AJ507799). The
AG876 sequence as determined corresponded to the circular,
latent plasmid form of the genome. The linear listing of the
rightward 5′ to 3′ strand was defined as starting one nucleotide
5′ to the sequence equivalent to the EcoRI site separating the
EcoRI Dhet and EcoRI I fragments in strain B95-8. This scheme
places sequences for the terminal repeat element adjacent to the
end of the listing, with three repeat copies of 558, 544 and 558
nuc as found in the cosmid sequenced (the EBV1 entry has four
copies). Sequences representing the major internal repeat ele-
ment IR1, of 3070 nuc per copy in AG876, were edited to give
7.6 copies as for the current EBV1 database entry (AJ507799).
These extended from nuc 11,986 to nuc 35,323.
The EBV genome contains many families of tandem repeats
of short sequence elements, in some cases showing sequence
variations among copies. Certain of these families presented
problems in sequence determination, which were handled as
follows. For the repeat family region (RF; nuc 7450 to 8019)
within the latent cycle origin of DNA replication oriP (Yates et
al., 1984), PCR analyses showed that the cosmid-cloned version
of RF was partly deleted relative to that in DNA of the
lymphoblastoid cell line (LCL) carrying EBV AG876, andsequencing templates for this region were therefore obtained by
PCR amplification from LCLDNA. The final sequence obtained
for the RF element comprised 19 copies of 30 nuc, with some
sequence differences among copies, and was considered to be
the best representation achievable; we note that sequence insta-
bilities in RF have been described by Fruscalzo et al. (2001). The
repeat set IR2 (nuc 38,281 to 39,944; repeat length 125 nuc; four
classes of variant) was set to 13 copies as determined for strain
AG876 by Dambaugh and Kieff (1982). The detail of sequence
variants in an internal portion of six copies of the set was not
resolved. We encountered a repeat set in the second exon of the
EBNA-3B gene (approximately nuc 85,241 to 85,980; 12
copies; repeat length 60 nuc; some sequence variation), where a
previous analysis of this gene in strain AG876 showed only three
repeat copies (Sample et al., 1990). We considered our sequence
of this set as most likely fully resolved. We note that the EBNA-
3B sequence has been reported for another EBV2 strain (MISP),
with 15 copies in this repeat family (Inoue et al., 1992). For the
IR3 set (nuc 96,759 to 97,466, a complex set of triplet repeats
within the coding sequence of the EBNA-1 gene), a version was
produced that accounted parsimoniously for all the shotgun
reads of the region, and whose length was compatible with the
analysis of Heller et al. (1982); this set was considered as most
likely fully resolved. The IR4 set (nuc 141,591 to 144,696;
repeat length 102 and 103 nuc; three classes of variant) was set to
30 copies, as determined by Dambaugh and Kieff (1982). In this
set, the detail of sequence variants in an internal portion of 25
copies was not resolved.
Sequences have been published for a number of loci within
the AG876 genome. These include the EBER transcript region
(Arrand et al., 1989); the EBNA-2 gene (Dambaugh et al., 1984);
repeat families IR2 and IR4 (Dambaugh and Kieff, 1982); the
BLLF1 (gp340) gene and neighboring sequences (Lees et al.,
1993); the EBNA-3A, EBNA-3B and EBNA-3C genes (Sample
et al., 1990); part of the EBNA-1 gene (Wrightham et al., 1995);
the LMP-1 gene (Sample et al., 1994); and part of the LMP-2A
gene (Busson et al., 1995). In all, these prior data represented
16% of the AG876 sequence. We found them to be identical to
our versions or almost so, with the one substantive exception
being the repeat set in the EBNA-3B gene mentioned above.
All differences between the EBV2 sequence and the EBV1
sequence, apart from the diverged EBNA-2 and EBNA-3 alleles,
were checked as a late-stage validation of the EBV2 sequence.
The assembled AG876 genome sequence (accession number
DQ279927) contained 172,764 nuc, base composition 59.5%
G+C.
Gene content of EBV2 strain AG876
The genome sequences of EBV1 and EBV2 AG876 are
closely collinear and, with the previously known exceptions of
the genes for EBNA-2 and the EBNA-3s, are near identical. It
was thus straightforward to transfer EBV1's genome annotation
to the AG876 sequence to yield the same gene layout. Two frame
shifting differences between the EBV1 and EBV2 sequences
were observed in regions judged plausibly protein coding, at
EBV2 residues 135,774/135,775 (a C residue was present
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was absent from EBV1). In collaboration with P. J. Farrell
(Imperial College, London), both were found experimentally to
represent errors in the EBV1 sequence. Interpretation of this
locus was then revised, resulting in definition of a new open
reading frame (ORF), BVLF1. We assessed all potential protein
coding ORFs in EBV2 by criteria of overlap with other ORFs
and by comparisons with the sequences of EBV1, CeHV-15 and
CalHV-3, with the aim of producing a conservative listing of
visible protein coding genes. Three further ORFs (BFRF1A,
BGLF3.5 and BDLF3.5) previously not annotated in EBV1
were identified. These three ORFs and BVLF1 all have ortho-
logues in the genus Rhadinovirus (the other genus of the Gam-
maherpesvirinae) and in the Betaherpesvirinae, and two have
orthologues in the Alphaherpesvirinae. Details of these four
EBV2 genes are listed in Table 1. Five other ORFs were
redefined from their EBV1 versions to start with ATG codons,
according to modern practice (BBLF2/BBLF3, BGLF4,
BTRF1, BALF3 and BNLF2b). Overall, we identified with
high confidence 80 genes encoding proteins in the EBV2 gen-
ome, with the members of two pairs of genes that overlap in the
same reading frame (LMP-2A/LMP-2B and BVRF2/BdRF1)
counted separately.
In addition, there were several putative EBV2 coding regions,
transferred from the EBV1 annotation, for which we reached a
position of significant doubt that they encode functional
proteins. These evaluations were based on considerations that
included (in different cases): positioning or lack of splicing or
translation signals; content of repeat sets whose units were not a
multiple of 3 nuc (and would thus translate cyclically in every
possible reading frame); extensive overlap with other ORFs
judged as genuine; and non-conservation in the CeHV-15 or
CalHV-3 sequences. Published data on expression of encoded
proteins were also considered. ORFs in this category were
BWRF1, BLLF2, BHLF1, LF3 and several (including BARF0,
A73 and RPMS1) encoded by a complex family of alternatively
spliced RNAs termed the BamHI A rightward transcripts
(BARTs) (Hitt et al., 1989; Sadler and Raab-Traub, 1995;
Smith et al., 1993). These dubious assignments range from quite
extensively analyzed genomic regions to little-studied features
that have been listed in the EBV1 annotation for many years and
may represent no more than loose ends from early efforts to
comprehend EBV1's gene complement.
Our comparisons also identified several discrepancies
between the EBV2 sequence and those of EBV's closestTable 1
Novel genes annotated in the genome of EBV2
Gene Sense Coding region
(nucs)
Size
(codons)
Rhadino
ortholog
BVLF1 − 135,636–136,454 272 ORF18
BFRF1A + 46,352–46,759 135 ORF67A
BGLF3.5 − 112,035–112,496 153 ORF35
BDLF3.5 − 117,539–117,772 77 ORF30
a Orthologues in the Rhadinovirus genus, the Alphaherpesvirinae subfamily and th
herpesvirus 2 (U20824), herpes simplex virus type 1 (X14112) and human cytomeg
b Attributes were derived from the above database entries.sequenced relatives, CeHV-15 and CalHV-3. These were in-
vestigated experimentally in collaboration with F. Wang (Har-
vard Medical School) and corrections made in the accessions for
CeHV-15 and CalHV-3. The genes defined or corrected were in
CeHV-15, EBNA-LP, BFRF1A, BcRF1 and BVLF1, and in
CalHV-3, BVLF1, BXLF2 and BGRF1/BDRF1.
Comparative analyses of the EBV1 and EBV2 genome
sequences
The EBV1 and AG876 sequences were aligned using
CLUSTAL W to give an alignment of length 173,695 cha-
racters. Fig. 1 shows the locations and magnitudes of insertion/
deletion (indel) and substitutional differences between the
aligned DNA sequences. The figure emphasizes that over most
of their lengths, the two genomes are highly similar, with few
indels and a sparse background of substitution divergence,
while the strongly diverged regions are sharply delimited. The
locations of variable genomic features that have already been
mentioned are indicated in the figure, plus that of the LMP-1
gene, and five other variable loci are labeled 1 to 5.
The EBNA-2, EBNA-3A, EBNA-3B and EBNA-3C genes,
whose distinct alleles define the two EBV types, are the loci of
major peaks for both classes of sequence differences. The
EBNA-1 gene, situated to the right of the EBNA-3 block, also
shows substantial indel and substitution divergence. The di-
verged loci labeled as 2 and 3 lie within the coding regions of,
respectively, the BPLF1 large tegument protein and the
BLLF1 gp340 virion glycoprotein, while locus 4 represents
an indel in an intron of the BZLF1 gene. In all cases, these
indel differences within genes result mainly from distinct copy
numbers in families of short repeat sequences. In the LMP-1
gene, there are two closely spaced deletions relative to EBV1
in EBV2 coding sequence, of 30 and 15 nuc (the latter in a
repeat family); these deletions were previously noted by
Sample et al. (1994).
Turning to diverged loci not in recognized genes, the repeat
families IR2, IR4 and TR register as indel peaks primarily
because of the differing numbers of repeat copies in the two
sequences. The RF element of oriP appears as a markedly
variable locus, and the study of Fruscalzo et al. (2001) has shown
that this repeat set is particularly volatile, with repeat copies
varying pronouncedly in sequence both within one genome and
among virus isolates, in addition to variability in copy number.
As an added complication, we found the RF region to be deletionvirus
ue a
Alphaherpes.
orthologue a
Betaherpes.
orthologue a
Attributes of
gene product b
– UL79 –
UL33 UL51 Role in DNA packaging
UL14 UL96 Tegument component
– UL91 –
e Betaherpesvirinae subfamily were represented respectively by genes of equine
alovirus (AY446894).
Fig. 1. Comparisons of the aligned EBV1 and EBV2 genome sequences. The complete EBV1 and EBV2 sequences were aligned using CLUSTAL W, to give an
alignment of overall length 173,695 residues including gapping characters. The GCG program PLOTSIMILARITY was then used to display separately the incidences
of addition/deletion differences (A) and of substitution differences (B) between the two genomes; for each measure, values are plotted as percentage differences over a
moving 600-character window. In panel A, the three highest peaks are shown truncated. Locations of variable regions are annotated with abbreviated names or with
numerals (1 to 5).
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any supposedly complete sequence. Lastly, there are two indel
differences not associated with multicopy tandem arrays: labeled
feature 1 marks a 105-nuc sequence downstream of the EBNA-2
transcript, which is duplicated in EBV2 but not in EBV1, and
feature 5 denotes a 74-nuc deletion in EBV1 relative to EBV2 in
an apparently non-coding region near the right origin of lytic
DNA replication.
Indel and nucleotide substitutional differences accounted
for 1.61% and 1.38% respectively of the complete alignment.
When the diverged EBNA-2 and EBNA-3 genes are excluded,
the values fall to 1.10% and 0.73% respectively. Such overall
levels of differences are comparable to those seen between
whole genome sequences for different isolates of other human
herpesvirus species (data not shown). We were interested in
the possibility that the diverged alleles in EBV1 and EBV2
might have arisen through the action of some specific
mutagenic process. We considered two such, namely the
system for hypermutational maturation of antibody affinity
and processes of methylation and deamination of cytosine
residues in DNA. In the first of these, the enzyme known as B
cell activation-induced cytidine deaminase (AID) is known to
have a central role (Muramatsu et al., 2000; Revy et al., 2000).
In activated B cells, AID acts to deaminate cytosine residues
to uracil in the V regions of transcribed immunoglobulin genes
with target preference for the motif 5′-RGYW/5′-WRCY
(Rogozin and Kolchanov, 1992; Yoshikawa et al., 2002).
Given that the EBNA genes are expressed during latent statesof EBV in B cells, we regarded as plausible that AID might
act as a specific mutator of EBNA genes. Regarding
methylation/deamination, it is known that enzymatic methyl-
ation of cytosine residues in the sequence 5′-CG plays a role
in EBV latency (reviewed by Tao and Robertson, 2003). Since
non-enzymatic hydrolytic deamination of 5′-methylcytosine to
thymine occurs at an appreciable rate, such methylation of
DNA leads to mutation and in fact has done so on a large
scale in the EBV genome as evidenced by general scarcity of
the sequence 5′-CG (Honess et al., 1989).
We examined patterns of substitution between the diverged
EBNA gene regions in the whole genome alignment, and
separately between the remaining regions in the alignment, by
computing frequencies of each single nucleotide difference in
the contexts of 5′-neighbors, 3′-neighbors and more extended
adjacent sequences. In summary, all possible classes of sub-
stitution were present, in terms of the residue differing and its
immediate 5′ or 3′ neighbors, and similar patterns were seen for
the EBNA-2 plus EBNA-3 loci and for the rest of the genome
(data not shown). We did not detect any indication that AID had
played a marked role in mutational divergence of the EBV1 and
EBV2 EBNA alleles. Changes involving 5′-CG were an abun-
dant class, and presumably, these resulted at least in part from
cytosine methylation and deamination. Relative levels of syno-
nymous and non-synonymous differences between EBV1 and
EBV2 in the EBNA-2 gene and the EBNA-3 genes were overall
indicative of purifying selection rather than neutral or positive
selection (McGeoch and Davison, 1999).
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The two types of EBV are defined by their possession of
substantially diverged alleles of four latent cycle genes. Our
complete sequence for an EBV2 strain now shows definitively
that a very high overall level of similarity exists across all other
regions of the EBV1 and EBV2 genomes, equivalent to that
seen between different isolates in other herpesvirus species.
Most of the small number of other marked differences between
the two EBV sequences represent variable copy numbers in
families of tandemly repeated elements and, as such, can be
discounted as likely to be of little or no functional significance.
We thus consider that EBV1 and EBV2 are to be regarded as
definitely members of the same species, differing significantly
only in allelic differences in a small subset of their genes.
The sizeable difference between the two alleles of the
EBNA-1 gene in Fig. 1 is eye catching, especially with its
proximity to the EBNA-3 region. However, previous studies of
many EBV isolates have demonstrated that the EBNA-1 gene
exhibits marked diversity, but that this does not show a strong
correlation with EBV type as defined by EBNA-2 and EBNA-
3 alleles (Bhatia et al., 1996; Habeshaw et al., 1999;
MacKenzie et al., 1999; Wrightham et al., 1995). Differences
in the LMP-1 gene similarly do not correlate with EBV type
(Sample et al., 1994). Conversely, however, Arrand et al.
(1989) noted that polymorphisms in the EBER region near the
left terminus of the genome did generally correspond with
EBV type. Overall, our current view, from comparison of the
complete genome sequences and from published data on local
polymorphisms for additional virus strains, is that the
haplotype pattern seen with EBNA-2, EBNA-3A, EBNA-3B
and EBNA-3C genes does not extend strongly to other large
scale, substantially diverged features of the EBV genome.
Quantitating the extent to which this pattern might apply to
variable features along the genome (such as single nucleotide
polymorphisms) would require sampling of sequences from
additional strains at a number of sites.
The evolutionary origins of the patterns of EBV genomic
divergence now visible are unclear. Two possible mechanisms
for generation of the two EBV types have been mooted
(McGeoch, 2001; McGeoch and Davison, 1999). The first
proposes that recombination events involving at least two
ancestral LCVs yielded two lineages corresponding to EBV1
and EBV2. Problems with this model are that it posits an other-
wise undetected parent, and it does not (in our view) account
very satisfactorily for the close correspondence between
boundaries of diverged regions and the boundaries of latent
gene blocks. The second proposedmechanism invokes a process
of preferential mutation of the four genes. Setting aside the fact
that the underlying reason for specific elevated mutation remains
undefined, our main reservation regarding this model is that it
does not account for only two distinct alleles for each gene rather
than a bush of diverged forms; this feature, however, could be
accommodated by proposing additionally that the two lineages
occupied non-overlapping niches during the period of allelic
divergence. Our examination of single nucleotide differences
between sections of the EBV1 and EBV2 genomes did not revealany simple pattern of substitution. Nonetheless, and regardless
of the precise mechanism, we believe that the fact that the genes
with diverged alleles are in active transcriptional states during
latent infection does present an attractive rationale for them
being uniquely exposed tomutational processes. It is noteworthy
that comparisons of EBV genes with those of its nearest
sequenced relative, CeHV-15, show that the latent cycle genes
are particularly diverged between the two (Rivailler et al.,
2002a), consistent with them having a highmutation rate relative
to other genes.
The occurrence of forms of EBV with reassorted EBNA-2
and EBNA-3 alleles (Burrows et al., 1996; Midgley et al., 2000;
Shim et al., 1998; Yao et al., 1996) demonstrates that at the
present time, the niches of EBV1 and EBV2 overlap to the
extent that dual infections and intertypic recombination occur.
Such recombination can also account for the lack of correlation
of variation in the EBNA-1 and LMP-1 loci with that in the
EBNA-2 gene and the EBNA-3 gene block. With availability of
complete sequences for both EBV types, it should now be
feasible to use polymorphisms across the genome to arrive at a
quantitative evaluation of incidence of recombination in a set of
EBV strains and thus a better understanding of the population
structure and evolution of this ubiquitous human pathogen.
Materials and methods
DNA sequence determination
Cultures of the LCL carrying EBV2 strain AG876 were gifts
from A. B. Rickinson (University of Birmingham, UK) and J. P.
Stewart (University of Liverpool, UK). LCLDNAwas subjected
to partial digestion with Sau3AI and used to make a cosmid
library with Supercos1 (Stratagene) as modified by Cunningham
and Davison (1993). The library was probed with 32P-labeled
plasmid-cloned EBV1 B95-8 BamHI fragments a, b and o
(Arrand et al., 1981) (gifts of J. R. Arrand, Paterson Institute,
Manchester, UK) and clones carrying EBV2 AG876 sequences
overlapping the probes were isolated and characterized by
terminal sequencing. Further probing with selected EBVAG876
cosmids and with a 380-bp PCR-generated fragment represent-
ing the left extremity of the genome gave a set of eight cosmids
which, on the basis of comparison of their terminal sequences
with the EBV1 genomic sequence, covered the entire AG876
genome with overlaps, except for one region of 2.1 kbp adjacent
to the left end of the linear genome listing. This gap in the cosmid
library was filled by amplifying the target region from LCL
DNA by PCR and cloning into M13mp18. DNA sequences of
the eight cosmids were determined by shotgun cloning into
M13mp18 and dideoxynucleotide methods with an ABI 377-
96XL sequencer. The RF region in oriPwas found to be prone to
deletion in the cosmid-cloned version, and sequencing templates
to resolve the region were obtained by PCR amplification from
LCL DNA across the repeat tract, agarose gel electrophoresis
and selection of the maximum length product, and cloning of
randomly sheared fragments into the plasmid vector pSTBlue-1
(Novagen). Other problem regions were analyzed by sequencing
from specific primers and by sequencing of M13-cloned PCR
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shotgun data and edited using GAP4 software with the base-
calling program PHRED (Ewing and Green, 1998; Ewing et al.,
1998; Staden et al., 2000).
Genomic sequences of LCVs used in comparative analyses
The data library entry for the complete genome sequence of
EBV1 B95-8 (Baer et al., 1984; accession number V01555) has
been supplemented with an 11.8 kbp sequence of EBV1 strain
Raji (Parker et al., 1990) to make good a deletion specific to
B95-8 and updated, to give a representation of the complete
EBV1 genome (de Jesus et al., 2003; accession number
AJ507799). Primary comparisons were with this sequence. In
collaboration with P. J. Farrell (Imperial College, London), we
carried out PCR and sequencing of B95-8 DNA that corrected
two residual errors. The resulting EBV1 sequence, with an
upgraded annotation, is available in accession number NC_
007605. The genome sequence for a second EBV1 strain, GD1,
has very recently become available (Zeng et al., 2005;
accession number AY961628), and this was utilized for
specific comparisons. Comparative analyses also included the
genome sequences of two other LCVs: CeHV-15 (Rivailler et
al., 2002a, accession number AY037858) and CalHV-3
(Rivailler et al., 2002b; accession number AF319782). We
reassessed these sequences in collaboration with F. Wang
(Harvard Medical School) by carrying out PCR and sequencing
of regions containing potential errors.
Computational analyses of molecular sequences
Sequence analyses used the GCG (Accelrys Inc.) and
EMBOSS packages. Alignments of whole EBV genome se-
quences were performed with CLUSTALW (Thompson et al.,
1994). Perl scripts were written to evaluate differences between
aligned EBV sequences.Acknowledgments
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